Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature.

OBJECTIVE Chronic cancer pain is often refractory and difficult to treat. Ketamine is a medication with evidence of efficacy in the treatment of chronic pain. DESIGN This article presents a synthesis of the data on ketamine for refractory cancer pain in adults and children. RESULTS There are five randomized, double-blind, controlled trials of ketamine use in cancer pain that demonstrate improvement in pain for some patients. There are six prospective, uncontrolled trials in cancer pain that also demonstrate improvement in pain scores for some patients. There are no randomized, controlled trials in children with cancer pain, although there are a few studies reflecting improved pain control with ketamine for children with cancer pain. Adverse events for adults on ketamine are most commonly somnolence, feelings of insobriety, nausea/vomiting, hallucinations, depersonalization/derealization, and drowsiness. However, when ketamine is combined with benzodiazepines, feelings of insobriety, hallucinations, and depersonalization/derealization are not reported. Children on ketamine have had few reported adverse effects, which include sedation, anorexia, urinary retention, and myoclonic movements. Recommended ketamine infusion dosages are from 0.05 to 0.5 mg/kg/h (intravenous or subcutaneous). Recommended oral dosages of ketamine are 0.2-0.5 mg/kg/dose two to three times daily with a maximum of 50 mg/dose three times daily. CONCLUSIONS Despite limitations in the breadth and depth of data available, there is evidence that ketamine may be a viable option for treatment-refractory cancer pain.

[1]  E. Kalso,et al.  Ketamine as an adjuvant to opioids for cancer pain. , 2017, The Cochrane database of systematic reviews.

[2]  E. Bruera,et al.  Pain in patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Dolan,et al.  Oral ketamine for children with chronic pain: a pilot phase 1 study. , 2013, Jornal de Pediatria.

[4]  J. Plummer,et al.  Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  O. P. Tandon,et al.  Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors , 2012, Human & experimental toxicology.

[6]  A. Perez,et al.  Ketamine Activates the l-Arginine/Nitric Oxide/Cyclic Guanosine Monophosphate Pathway to Induce Peripheral Antinociception in Rats , 2011, Anesthesia and analgesia.

[7]  L. Devi,et al.  Potentiation of μ‐opioid receptor‐mediated signaling by ketamine , 2011, Journal of neurochemistry.

[8]  A. Dahan,et al.  Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases , 2011, PAIN.

[9]  Gregory Luke Larkin,et al.  A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. , 2011, The international journal of neuropsychopharmacology.

[10]  M. van Kleef,et al.  23. Pain in Patients with Cancer , 2011, Pain practice : the official journal of World Institute of Pain.

[11]  L. Arendt-Nielsen,et al.  A Translational Study of the Effects of Ketamine and Pregabalin on Temporal Summation of Experimental Pain , 2011, Regional Anesthesia & Pain Medicine.

[12]  M. Feria,et al.  A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio. , 2011, Journal of pain and symptom management.

[13]  C. Loprinzi,et al.  A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA , 2011, Supportive Care in Cancer.

[14]  C. Woolf.  Central sensitization: Implications for the diagnosis and treatment of pain , 2011, PAIN.

[15]  Tilo Kircher,et al.  Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency , 2011, NeuroImage.

[16]  B. Bhattarai,et al.  Ketamine gargling and postoperative sore throat. , 2010, JNMA; journal of the Nepal Medical Association.

[17]  M. Ashby,et al.  The Effectiveness and Adverse Effects profile of “Burst” Ketamine in Refractory Cancer Pain: The Vcog Pm 1-00 Study , 2010, Journal of palliative care.

[18]  M. Hollmann,et al.  Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells. , 2010, British journal of anaesthesia.

[19]  P. Neuvonen,et al.  Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S‐ketamine , 2010, European journal of pain.

[20]  P. Bemt,et al.  Use of oral ketamine in chronic pain management: A review , 2010, European journal of pain.

[21]  S. Azad,et al.  Effects of low‐dose intranasal (S)‐ketamine in patients with neuropathic pain , 2010, European journal of pain.

[22]  D. Charney,et al.  Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.

[23]  Rabia S. Atayee,et al.  Ketamine mouthwash for mucositis pain. , 2009, Journal of palliative medicine.

[24]  J. Marinus,et al.  Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.

[25]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[26]  C. Coté,et al.  Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. , 2009, Annals of emergency medicine.

[27]  D. Borsook.  Ketamine and chronic pain – Going the distance , 2009, PAIN.

[28]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[29]  R. Bachur,et al.  Serious Adverse Events During Procedural Sedation With Ketamine , 2009, Pediatric emergency care.

[30]  W. Zempsky,et al.  Use of Continuous Intravenous Ketamine for End-Stage Cancer Pain in Children , 2009, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[31]  R. Bell.  Ketamine for chronic non-cancer pain , 2009, PAIN.

[32]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[33]  M. Grégoire,et al.  A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007). , 2008, Urology.

[34]  Silvia García,et al.  Prolonged sedation and airway complications after administration of an inadvertent ketamine overdose in emergency department. , 2008, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[35]  K. A. Trujillo,et al.  Increased Response to Ketamine Following Treatment at Long Intervals: Implications for Intermittent Use , 2008, Biological Psychiatry.

[36]  Z. Quezado,et al.  Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. , 2007, The journal of pain : official journal of the American Pain Society.

[37]  Tomasz R. Okon.  Ketamine: an introduction for the pain and palliative medicine physician. , 2007, Pain physician.

[38]  A. Ben-Ari,et al.  Chronic administration of ketamine for analgesia. , 2007, Journal of pain & palliative care pharmacotherapy.

[39]  S. Schug,et al.  The role of ketamine in pain management. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[40]  B. Anderson,et al.  Recent developments in the pharmacological management of pain in children , 2006, Current opinion in anaesthesiology.

[41]  S. Mercadante,et al.  Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. , 2005, Journal of pain and symptom management.

[42]  D. Troost,et al.  Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain , 2005, Pain.

[43]  J. Body,et al.  Successful use of ketamine for intractable cancer pain , 2005, Supportive Care in Cancer.

[44]  R. Viola,et al.  Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. , 2005, Journal of palliative medicine.

[45]  S. Malherbe,et al.  Intravenous Ketamine Infusion as an Adjuvant to Morphine in a 2-Year-Old With Severe Cancer Pain From Metastatic Neuroblastoma. , 2004, Journal of pediatric hematology/oncology.

[46]  C. Streutker,et al.  Ketamine-associated ulcerative cystitis: a new clinical entity. , 2004, Urology.

[47]  Karen J. Roberts,et al.  Going the distance. , 2003, The American journal of nursing.

[48]  E. Kalso,et al.  Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. , 2003, Journal of pain and symptom management.

[49]  T. Ushida,et al.  Analgesic Effects of Ketamine Ointment in Patients With Complex Regional Pain Syndrome Type 1 , 2002, Regional Anesthesia & Pain Medicine.

[50]  S. Kaasa,et al.  Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. , 2001, Journal of pediatric hematology/oncology.

[51]  M. Ashby,et al.  "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. , 2001, Journal of pain and symptom management.

[52]  H. Curran,et al.  In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. , 2001, Addiction.

[53]  S. Mercadante,et al.  Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. , 2000, Journal of pain and symptom management.

[54]  S. McDonald,et al.  Cognitive impairment among methadone maintenance patients. , 2000, Addiction.

[55]  G. Lauretti,et al.  Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. , 1999, Journal of clinical anesthesia.

[56]  G. Lauretti,et al.  Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. , 1999, Anesthesiology.

[57]  E. Masliah,et al.  Subpial vacuolar myelopathy after intrathecal ketamine: report of a case , 1997, Pain.

[58]  T. Jensen,et al.  Oral ketamine therapy in the treatment of postamputation stump pain , 1997, Acta anaesthesiologica Scandinavica.

[59]  S. Ho,et al.  Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[60]  L. Arendt-Nielsen,et al.  NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride , 1996, Pain.

[61]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[62]  D. Reich,et al.  Ketamine: an update on the first twenty-five years of clinical experience , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[63]  M. Mayer,et al.  Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones , 1984, Nature.

[64]  J. Clements,et al.  Pharmacokinetics and analgesic effects of i.m. and oral ketamine. , 1982, British journal of anaesthesia.

[65]  M. van Kleef,et al.  Evidence-Based Interventional Pain Medicine According to Clinical Diagnoses 23. Pain in Patients with Cancer , 2011 .

[66]  L. Papile.  Early Exposure to Anesthesia and Learning Disabilities in a Population-based Birth Cohort , 2010 .

[67]  S. Abram.  Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study , 2010 .

[68]  A. Boyaci,et al.  Oral ketamine for pain relief in a child with abdominal malignancy. , 2009, Pain medicine.

[69]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions : Explanation and Elaboration , 2009 .

[70]  Martin S. Angst,et al.  A Qualitative Systematic Review , 2006 .

[71]  S. Bhatnagar,et al.  Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. , 2002, Journal of pain and symptom management.

[72]  Alban Latremoliere,et al.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity. , 2009, The journal of pain : official journal of the American Pain Society.